| Methods |
4‐ to 5‐week single‐blind placebo run‐in; inclusion criteria= mean sitting DBP 95‐110 mm Hg at 2 consecutive visits 1 week apart; 8‐week double‐blind treatment |
| Participants |
Fosinopril 20 mg: n=16(7 males,9 females); mean age=48.8(11.6) years; baseline sitting SBP=149.7(12.0) mm Hg, DBP=101.9(4.4) mm Hg, HR=72.9 bpm;
Placebo: n=17(2 males,15 females); mean age=53.2(7.0) years; baseline sitting SBP=146.6(9.9) mm Hg, DBP=100.3(3.7) mm Hg, HR=73.4 bpm |
| Interventions |
Fosinopril 20 mg once daily;
Placebo |
| Outcomes |
Mean change from baseline in trough sitting SBP/DBP using mercury sphygmomanometer;
WDAE |
| Notes |
BP change and SD of change reported; endpoint BP and SD not reported; BP data from Table 2, p. I‐209; Jadad score=3; funding source= Bristol‐Myers Squibb |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment? |
Unclear risk |
B ‐ Unclear |
